Reference | </br> 1. Saydoff, Joel A.; Garcia, Rolando A. G.; Browne, Susan E.; Liu, Liansheng; Sheng, Jin; Brenneman, Denise; Hu, Zhongyi; Cardin, Sylvain; Gonzalez, Alexis; von Borstel, Reid W.; Gregorio, Jason; Burr, Holly; Beal, M. Flint. Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington/’s disease. Neurobiology of Disease (2006), 24(3), 455-465. CODEN: NUDIEM ISSN:0969-9961. CAN 146:266494 AN 2006:1245538 </br>2. Doroshow, James H.; McCoy, Sheryl; Macdonald, John S.; Issell, Brian F.; Patel, Taral; Cobb, Patrick W.; Yost, Kathleen J.; Abbruzzese, James L. Phase II trial of PN401, 5-FU, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach: A Southwest Oncology Group study. Investigational New Drugs (2006), 24(6), 537-542. CODEN: INNDDK ISSN:0167-6997. CAN 146:414364 AN 2006:834313 </br>3. Saif, Muhammad Wasif; Borstel, Reid. 5-Fluorouracil dose escalation enabled with PN401 (triacetyluridine): toxicity reduction and increased antitumor activity in mice. Cancer Chemotherapy and Pharmacology (2006), 58(1), 136-142. CODEN: CCPHDZ ISSN:0344-5704. CAN 145:327796 AN 2006:375032 </br>4. Garcia, Rolando A. G.; Liu, Liansheng; Hu, Zhongyi; Gonzalez, Alexis; von Borstel, Reid W.; Saydoff, Joel A. Severe cytochrome c oxidase inhibition in vivo does not induce a pyrimidine deficiency; neuroprotective action of oral uridine prodrug PN401 requires supraphysiological levels of uridine. Brain Research (2005), 1066(1-2), 164-171. CODEN: BRREAP ISSN:0006-8993. CAN 144:81045 AN 2005:1319808 </br>5. Saydoff, J.; Liu, L.; Hu, Z.; von Borstel, R. Uridine prodrug PN401 is beneficial in APP2576 mice and models for chemical hypoxia and oxidative stress. Vascular Dementia, International Congress, 3rd, Prague, Czech Republic, Oct. 23-26, 2003 (2003), 241-245. CODEN: 69GVAS CAN 143:71599 AN 2005:397109 </br>6. Saydoff, Joel A.; Liu, Lian Sheng; Garcia, Rolando A. G.; Hu, Zhongyi; Li, Donna; von Borstel, Reid W. Oral uridine pro-drug PN401 decreases neurodegeneration, behavioral impairment, weight loss and mortality in the 3-nitropropionic acid mitochondrial toxin model of Huntington/’s disease. Brain Research (2003), 994(1), 44-54. CODEN: BRREAP ISSN:0006-8993. CAN 140:174995 AN 2003:923611 </br>7. Hidalgo, Manuel; Villalona-Calero, Miguel A.; Eckhardt, S. Gail; Drengler, Ronald L.; Rodriguez, Gladys; Hammond, Lisa A.; Diab, Sami G.; Weiss, Geoffrey; Garner, Allison M.; Campbell, Elizabeth; Davidson, Karen; Louie, Arthur; O/’Neil, James D.; Von Borstel, Reid; Von Hoff, Daniel D.; Rowinsky, Eric K. Phase I and pharmacologic study of PN401 and fluorouracil in patients with advanced solid malignancies. Journal of Clinical Oncology (2000), 18(1), 167-177. CODEN: JCONDN ISSN:0732-183X. CAN 132:102547 AN 2000:61094 </br>8. Kelsen, David P.; Martin, Dan; O/’neil, James; Schwartz, Gary; Saltz, Leonard; Sung, Michael T.; Von Borstel, Reid; Bertino, Joseph. Phase I trial of PN401, an oral prodrug of uridine, to prevent toxicity from fluorouracil in patients with advanced cancer. Journal of Clinical Oncology (1997), 15(4), 1511-1517. CODEN: JCONDN ISSN:0732-183X. CAN 126:325035 AN 1997:283216</br>
|